November 2024 – Page 22

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies

Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts

6 months ago talkbio0Tagged amgen, MariTide, Obesity, Phase 3 program, pipeline, strategic refocus

Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program

European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market

6 months ago talkbio0Tagged Commission, competition, Copaxone, Dominance, European (ethnic group), Market, Mississippi (geographic location), MS, tactics, Teva

Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance

FDA Advisory Committee Votes Against Zynquista for Type 1 Diabetes and Chronic Kidney Disease, Despite Support for Subgroup Benefits

6 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Advisory Committees, Chronic Kidney Diseases, Diabetes Mellitus, Insulin-Dependent, Glycemic Control, Inhibitor, lexicon, SGLT1/SGLT2, United States Food and Drug Administration, Zynquista

FDA Advisory Committee, Zynquista (sotagliflozin), Type 1 Diabetes (T1D), Chronic Kidney Disease (CKD), Glycemic Control, SGLT1/SGLT2 Inhibitor, Lexicon Pharmaceuticals

Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

6 months ago talkbio0Tagged Alzheimer 's disease, Default Mode Network, Disease Progression, neuromodulation therapy, Non-invasive therapy, Personalized Treatment, Sinaptica, Stimulation procedure, Structure of precuneus

Sinaptica Therapeutics, Neuromodulation therapy, Alzheimer’s disease, Disease progression reduction, Personalized treatment, Non-invasive therapy, Default Mode Network (DMN), Precuneus stimulation